Salute e Benessere
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year.
"This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan , PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic."
Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill . In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms.
Focal Medical was co-founded by:
Their iontophoresis system is designed to deliver , an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity.
"After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers , Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers."
Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in
Bradenton, FL ; Houston, TX ;
Raleigh, NC ; and Torino, Italy , the company focuses on combination drug-device platforms for chronic and complex conditions.
Visit: www.continuitybiosciences.com
Focal Medical, Inc. develops energy-based chemotherapy delivery systems that enable direct application of drugs to tumor sites. Its mission is to improve efficacy and reduce toxicity in the treatment of solid tumors, with an initial focus on pancreatic cancer.
Visit: www.focalmedical.co
Logo - https://mma.prnewswire.com/media/2555793/Continuity_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/continuity-biosciences-acquires-focal-medical-to-advance-targeted-drug-delivery-for-pancreatic-cancer-302472131.html